Global priority multidrug-resistant pathogens do not resist photodynamic therapy

Autor(es)

Sabino, Caetano Padial ^{[1, 2]} ; Wainwright, Mark ^[3] ; Ribeiro, Martha Simoes ^[4] ; Sellera, Fabio Parra ^[5] ; dos Anjos, Carolina ^[5] ; Baptista, Mauricio da Silva ^[6] ; Lincopan, Nilton ^{[7, 1, 8]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Clin Anal, Sao Paulo - Brazil

^[2] Sci & Commercial LTD, BioLambda, Sao Paulo, SP - Brazil

^[3] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Liverpool, Merseyside - England

^[4] Natl Commiss Nucl Energy, Ctr Lasers & Applicat Nucl & Energy Res Inst, Sao Paulo, SP - Brazil

^[5] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Internal Med, Sao Paulo - Brazil

^[6] Univ Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, SP - Brazil

^[7] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo - Brazil

^[8] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo, Brazil.Sabino, Caetano Padial, Sci & Commercial LTD, BioLambda, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY; v. 208, JUL 2020.
• Citações Web of Science: 13

Resumo

Microbial drug-resistance demands immediate implementation of novel therapeutic strategies. Antimicrobial photodynamic therapy (aPDT) combines the administration of a photosensitizer (PS) compound with low-irradiance light to induce photochemical reactions that yield reactive oxygen species (ROS). Since ROS react with nearly all biomolecules, aPDT offers a powerful multitarget method to avoid selection of drug-resistant strains. In this study, we assayed photodynamic inactivation under a standardized method, combining methylene blue (MB) as PS and red light, against global priority pathogens. The species tested include Acinetobacter baumannii, Klebsiella aerogenes, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecium, Enterococcus faecalis, Staphylococcus aureus, Candida albicans and Cryptococcus neoformans. Our strain collection presents resistance to all tested antimicrobials ( > 50). All drug-resistant strains were compared to their drugsensitive counterparts. Regardless of resistance phenotype, MB-aPDT presented species-specific dose-response kinetics. More than 5log(10) reduction was observed within less than 75 s of illumination for A. baumannii, E. coli, E. faecium, E. faecalis and S. aureus and within less than 7 min for K. aerogenes, K. pneumoniae, P. aeruginosa, C. albicans and C. neoformans. No signs of correlations in between drug-resistance profiles and aPDT sensitivity were observed. Therefore, MB-aPDT can provide effective therapeutic protocols for a very broad spectrum of pathogens. Hence, we believe that this study represents a very important step to bring aPDT closer to implementation into mainstream medical practices. (AU)

• Processo FAPESP: 17/22406-0 - Desenvolvimento de equipamento inteligente para aplicação clínica de fototerapias com ajuste dosimétrico automático e pagamento sob demanda
• Beneficiário: Caetano Padial Sabino
• Linha de fomento: Auxílio à Pesquisa - Pesquisa Inovativa em Pequenas Empresas - PIPE
• Processo FAPESP: 16/25095-2 - Fotoinativação bacteriana de patógenos da mastite por meio da luz azul: mecanismos de ação e segurança celular - estudo pré clínico
• Beneficiário: Carolina dos Anjos
• Linha de fomento: Bolsas no Brasil - Doutorado
• Processo FAPESP: 16/08593-9 - Pan-resistoma de Klebsiella pneumoniae e Escherichia coli produtoras de beta-lactamases (KPC-2, CTX-M-8, CTX-M-15) endêmicas no Brasil
• Beneficiário: Nilton Erbet Lincopan Huenuman
• Linha de fomento: Auxílio à Pesquisa - Regular
• Processo FAPESP: 13/07937-8 - Redoxoma
• Beneficiário: Ohara Augusto
• Linha de fomento: Auxílio à Pesquisa - Centros de Pesquisa, Inovação e Difusão - CEPIDs